Alirocumab Administration Experience to Achieve Low Density Lipoprotein Cholesterol Target Levels in Secondary Prevention of Cardiovascular Disease

• Váldodahkkit: A. E. Nikitin (Dahkki), E. E. Averin (Dahkki), D. E. Rozhkov (Dahkki), A. V. Sozykin (Dahkki), G. A. Procenko (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Столичная издательская компания, 2020-03-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Aim. To study the effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, alirocumab, on lipid levels in patients who receive secondary prevention of cardiovascular diseases (CVD) and require enhanced lipid-lowering therapy.Material and methods. The study included 49 patients (ag...